CVE-2009-4078

Description

Multiple cross-site scripting (XSS) vulnerabilities in Redmine 0.8.5 and earlier allow remote attackers to inject arbitrary web script or HTML via unspecified vectors.

Category

4.3
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.70% Top 30%
Vendor Advisory secunia.com Vendor Advisory vupen.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://www.vupen.com/english/advisories/2009/3291 vdb entry patch vendor advisory
http://rubyforge.org/frs/shownotes.php?release_id=41108 patch
http://www.securityfocus.com/bid/37066 vdb entry
http://www.redmine.org/wiki/redmine/Changelog#v086-2009-11-04 patch
http://jvn.jp/en/jp/JVN87341298/index.html third party advisory patch
https://exchange.xforce.ibmcloud.com/vulnerabilities/54333 vdb entry
http://jvndb.jvn.jp/ja/contents/2009/JVNDB-2009-000073.html third party advisory patch
http://jvn.jp/en/jp/JVN01245481/index.html third party advisory patch
http://secunia.com/advisories/37420 third party advisory vendor advisory

Frequently Asked Questions

What is the severity of CVE-2009-4078?
CVE-2009-4078 has been scored as a medium severity vulnerability.
How to fix CVE-2009-4078?
To fix CVE-2009-4078, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2009-4078 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2009-4078 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.